Atazanavir is a highly potent HIV-1 protease inhibitor. Has shown to be generally more potent than the five currently approved HIV-1 Prt inhibitors. Atazanavir (BMS-232632) inhibited the proteolytic cleavage of the viral gag precursor p55 polyprotein in a dose-dependent manner, with a EC 50 of approximately 47 nM. Also highly selective for HIV-1 Prt and exhibits cytotoxicity only at concentrations 6,500- to 23,000-fold higher than that required for anti-HIV activity. Atazanavir (BMS-232632) may be an effective HIV-1 inhibitor that may be utilized in a variety of different drug combinations.
Palella, F.J. Jr., et al.: N. Engl. J. Med., 338(13), 853 (1998), Nolan, D., et al.: Drugs, 63(23), 2555 (2003), Musial, B.L., et al.: Am. J. Health Syst. Pharm., 61, 1365 (2004), Wood, R., et al.: J. Acquir. Immune Defic. Syndr., 36, 684 (2004),
See how others have used Atazanavir. Click on the entry to view the PubMed entry .
PMID: # 26189431 Mendonza, A. et al. 2016. J Clin Pharmacol. 56: 355-64.
PMID: # 27249967 Costa, S. et al. 2016. Parasitology research.
PMID: # 25815168 Hara, M. et al. 2015. Clin Kidney J. 8: 137-42.
PMID: # 23750830 Chang, JH. et al. 2013. Mol. Pharm. 10: 3067-75.
PMID: # 21068005 Leroyer, S. et al. 2011. J. Lipid Res. 52: 207-20.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.